Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
Notice for sotatercept (Merck Sharp & Dohme (Australia) Pty Ltd)
Active ingredients
sotatercept
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of pulmonary arterial hypertension (PAH) in adult patients on standard of care with WHO Functional Class (FC) II to III, to improve exercise capacity, provide clinical improvement, improve WHO FC and delay disease progression, including to reduce the risk of death and hospitalisation for PAH
Therapeutic area
Cardiovascular